VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Marcia Midori Shinzato Universidade Federal da Grande Dourados, Mato Grosso do Sul-Brazil Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below Thanks for the authors for this interesting study, as rheumatologist we suggested 1) A more current definition of rheumatoid arthritis in the introduction using more up-to-date references. Reply: Thanks for your specific comment, we had cited up-to-date references ( 1st,5th, 7th and 9th references) in the section of introduction.
2) In material and methods, I would like to know how hearing loss was defined (by audiometry, by ENT physician). Reply: Thanks for your thoughtful comment. In this study, the diagnoses of hearing loss were based on the ICD-9 codes, as determined by qualified clinical physicians (not always ENT physician) for the strictly audited reimbursement process. All insurance claims are scrutinized and coded by medical reimbursement specialists and peer reviewed according to the standard criteria for diagnoses in the study. Moreover, incorrect diagnoses or coding mistakes result in considerable penalties for the physicians.
The reliability and validity of the NHI research database for epidemiologic studies have been reported previously (reference 16: Cheng CL et al.) . Therefore, the diagnoses and coding in this study should be highly reliable. In general, hearing loss is diagnosed by ENT physician or other clinical physician based on audiometry findings. We have specified in the revision: "In general, HL was diagnosed based on the audiometry test." (Please see text: page 8 paragraph 3 line 2-3.) [27, 33] , CKD [34, 35] and thyroid disease [36] [37] [38] . We have addressed the selection of comorbidities in the Discussion section. We have added hypothyroidism and autoimmune diseases (including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis, and vasculitis) in the list of comorbidities. (Table 1-3) . RA may be related to both hyperand hypo-thyroidism (text: references 36-38). Table 1 : Please discuss why there are no significant differences in the prevalence of most comorbidities, since there are strong data that these comorbidities e.g. DM are more prevalent in RA patients. Reply: Thank you for the comment. The study population is prevalent with younger in both age matched cohorts (Table 1) . Therefore, most comorbidities were not significantly different between 2 cohorts . But, these comorbidities are associated with HL risk, stronger for the RA cohort than controls (Table 3) . In the revision, we stated: "Evidences have shown that patients with RA are prevalent with comorbidities, such as IHD [24] [25] [26] , stroke [27] , hypertension [28, 29] , diabetes [30] [31] [32] , dyslipidemia [27, 33] , CKD [34, 35] and thyroid disease [36] [37] [38] . In this study, however, the study populations in both cohorts were young. The baseline prevalence rates of most comorbidities between the 2 cohorts were not significantly different, except that CKD and autoimmune diseases were more prevalent in patients with RA than in controls without RA at the baseline. It is clear that most of the comorbidities are associated with further increased incidence of HL, greater for the RA cohort than for the non-RA cohort, except hypothyroidism, and autoimmune diseases (Table 3) . (Please see page 15.) 3. What treatment did patients received during this period? Reply: Thank you for the inspirational comment. We further analyzed data on medications available from the insurance, including NSAIDs, prednisolone, DMARDs (including hydroxychloroquine, sulfasalazine, methotrexate, and leflunomide), and TNF (including etanercept and adalimumab) for patients with RA (page 10 lines 2-9). We have included findings (Table 4) in the revised manuscript and the interpretation on page 11 last 2 lines and page 12 lines 1-5.
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4. Do consider to extract data for disease activity to boost your results. Reply: Because the disease activity and DAS-28 were not available from the Taiwan National Health Insurance Research Database (NHIRD). It's the limitation of this study. The suggestion inspire us to consider using our own clinic data as another study because DAS28 data are available at our hospital.
5. please clarify how HL was diagnosed in the patients. Reply: Thank you for your thoughtful comment. In this study, the diagnoses of hearing loss were based on the ICD-9 codes, as determined by qualified clinical physicians (not always ENT physician) for the strictly audited reimbursement process. All insurance claims are scrutinized and coded by medical reimbursement specialists and peer reviewed according to the standard criteria for diagnoses in the study. Moreover, incorrect diagnoses or coding mistakes result in considerable penalties for the physicians. The reliability and validity of the NHI research database for epidemiologic investigations have been reported previously (reference: Cheng CL et al.). Therefore, the diagnoses and coding in this study should be highly reliable. In general, hearing loss is diagnosed by ENT physician or other clinical physician based on audiometry findings. We have specified in the revision: "In general, HL was diagnosed based on the audiometry test." (Please see text: page 8 paragraph 3 line 2-3.) 6. consider to update reference list. some of them are old. Reply: Thanks for the suggestion. We have cited near 20 articles in the reference list in addition. 8. the authors should consider to improve the discussion part. the discussion part is not informative. in addition, consider to discuss the IHD as a risk factor for HL with more details. Reply: Thanks for the suggestion. We have elaborated more information in the Discussion part (Please see paragraphs 3,4 and 6. Paragraphs 3 and 4 elaborate the contribution of comorbidities in HL, including IHD in paragraph 4. Paragraph 6 discussed the treatment effectiveness of RA therapy in reducing HL risk.). Your comment #3 giving us an opportunity to improve this study. We consider the findings improve the informative issue. Thanks. Table 4 for the findings. These medications are associated with reduced risk of HL. We are pleased for having conducted this part of additional data analysis. We have included findings (Table 4 , please see last page in this reply) in the revised manuscript; please see the interpretation on page 11 last 2 lines and page 12 lines 1-5: " Table 4 shows that medications were associated with reduced incident HL for RA patients. Near 99% of RA patients used NSAIDs and users had a HL incidence of 2.98 per 1000 person-years, with an aHR of 0.12 (95% CI = 0.07-0.20) compared with non-users who had an incidence of 30.1 per 1000 person-years for HL. RA patients on medications of TNF (n = 2706) had the lowest HL incidence of 1.17 per 1000 person-years with an aHR of 0.40 (95% CI = 0.27-0.59), compared with non-users who had an incidence of 3.45 per 1000 person-years." 3. The authors need to explain how they decide to include the current variables. Reply: Thanks for reminding. We have elaborate the concern in the Discussion section Paragraph 3: "Evidences have shown that patients with RA are prevalent with comorbidities, such as IHD [24] [25] [26] , stroke [27] , hypertension [28, 29] , diabetes [30] [31] [32] , dyslipidemia [27, 33] , CKD [34, 35] and thyroid disease [36] [37] [38] . In this study, however, the study populations in both cohorts were young. The baseline prevalence rates of most comorbidities between the 2 cohorts were not significantly different, except that CKD and autoimmune diseases were more prevalent in patients with RA than in controls without RA at the baseline (Table 1) . It is clear that most of the comorbidities are associated with further increased incidence of HL, greater for the RA cohort than for the non-RA cohort, except hypothyroidism, and autoimmune diseases (Table 3) ."
